Comparing the efficacy of three different doses of intravenous ketorolac on postoperative analgesia in obese patients undergoing laparoscopic cholecystectomy

A prospective randomized parallel-group study comparing the analgesic efficacy and safety of three scheduled intravenous ketorolac regimens in obese patients undergoing laparoscopic cholecystectomy

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

PACTR

Registry ID

PACTR202605602247405

Enrollment

Registered

2026-05-26

Start date

2026-04-01

Completion date

Unknown

Last updated

2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anaesthesia

Interventions

Ketorolac

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: • Age 18–64 years (non-elderly). • BMI 30 -40 (mild and moderate obese). • ASA physical status II OR III. • Scheduled elective laparoscopic cholecystectomy under general anesthesia. • Able to understand the VAS and give informed consent.

Exclusion criteria

Exclusion criteria: • Patient refusal. • Known hypersensitivity to study medications. • Chronic opioid use. 4 • Preexisting renal impairment: -Baseline serum creatinine >1.4 mg/dL. -Renal impairment by history. -Nephropathy or CKD by imaging. -Long standing DM. -Uncontrolled DM. • Active peptic ulcer disease or history of gastrointestinal bleeding. • Coagulopathy. • Conversion to open cholecystectomy intraoperatively.

Design outcomes

Primary

Measure	Time frame
Cumulative opioid consumption (IV morphine equivalent).	—

Secondary

Measure	Time frame
Mean pain intensity (VAS): Measured at rest over the first 24 hours (time points: 0, 2, 4, 6, 12, 24 hours postoperatively).;Time to first rescue analgesic.;Incidence of opioid-related side effects (nausea/vomiting, sedation).;Assess safety: changes in serum creatinine at 24 hours, incidence of clinically significant bleeding or hemoglobin drop(change in bleeding time / surgical drain output / need for intervention), and other adverse events.	—

Measure

Time frame

Mean pain intensity (VAS): Measured at rest over the first 24 hours (time points: 0, 2, 4, 6, 12, 24 hours postoperatively).;Time to first rescue analgesic.;Incidence of opioid-related side effects (nausea/vomiting, sedation).;Assess safety: changes in serum creatinine at 24 hours, incidence of clinically significant bleeding or hemoglobin drop(change in bleeding time / surgical drain output / need for intervention), and other adverse events.

—

Countries

Egypt

Contacts

Public ContactHanaa;Reem Mahmoud Elbendary;Abdelraouf Elsharkawy

Professor ;Professor

hanaa_elbendary@yahoo.com;reemraouf64@gmail.com+201005781768;+201006151100

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Sep 19, 2026